- BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Growth Velocity of 3.03 cm/yr with No Treatment-Related Adverse EventsYahoo finance
- BBIO stock erupts after shattering expectations and rivals in dwarfism studyInvestor Business Daily
- BridgeBio targets $172.5 million raise after dwarfism drug study data – Reutersbusiness journals
- BridgeBio’s Dwarfism Candidate Shows Favorable Height Increase and Safety ProfileYahoo finance
- BridgeBio Stock Rebounds 50% on New Dwarfism Therapy DataMarketWatch